MPs Warn UK Deals with President Trump are 'Unstable'.

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's recent agreements with Donald Trump are "lacking a solid foundation." This stems from revelations that a much-touted deal on medicines, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any formal legal text beyond vague headline terms contained within government press releases.

Lacking Legal Footing

The deal on drug tariffs, described as a "significant" achievement, remains an "broad understanding" without formal ratification. It has been highlighted that the public statements from the UK and US governments present the deal in markedly contrasting terms. The British version emphasizes securing "duty-free access" as a singular success, while the American announcement dwells on the commitment for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has agreed to terms to increase medicine costs in return for only a verbal promise from President Trump," commented David Henig, a trade expert. "History shows he has form for not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Worries have been heightened by Washington's move to suspend the £31bn "tech prosperity deal", which was previously described as "a transformative pact" in the bilateral relationship. The US pointed to a failure to advance from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions agreed to for British farmers as part of an earlier tariff deal have yet to be formally ratified by the US, despite a imminent January deadline. "Our understanding is that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Privately, ministers have expressed concerns that the government's deals with Washington are lacking substance. One minister was quoted as stating the series of agreements as "built on sand," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, argued: "Perhaps most shocking than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a trustworthy negotiator. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Officials have downplayed the possibility of the US withdrawing from the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it more concrete than the paused tech deal.

Officials concede that unpredictability is a feature of dealing with the current US leadership. However, they contend that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

However, delays have emerged in enacting the broader trade deal. Promised quotas on beef exports have not materialized, and the commitment to "reduce steel tariffs to zero" has remains unmet, with tariffs fixed at 25%.

Moving forward, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.